相关实验视频
Updated: Sep 14, 2025
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
55.2K
维生素C与安慰剂在儿科败血症休克 (VITACiPS) - 一个随机对照试验
Jhuma Sankar1, Aravindhan Manoharan1, Rakesh Lodha1
1Division of Pediatric Pulmonology and Intensive Care, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Journal of intensive care medicine
|July 25, 2025
概括
这项研究发现,静脉注射维生素C并没有显著改善败血性休克儿童的器官功能障碍. 因此,不建议在儿科败血症休克治疗中进行常规使用.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 败血症的研究研究.
- 在重症患者的营养支持.
背景情况:
- 儿童的感染性休克治疗选择有限.
- 静脉注射维生素C在成人败血症休克中表现出不同的结果.
- 在小儿性休克中维生素C的证据很少.
研究的目的:
- 评估静脉注射维生素C作为儿科败血症休克的辅助疗法的疗效.
- 确定维生素C对有机器功能障碍和败血症儿童死亡率的影响.
主要方法:
- 一项随机,双盲,安慰剂对照试验在儿童重症监护病房进行.
- 17岁以下的患有败血性休克的儿童在72小时内接受了静脉注射维生素C或糖安慰剂.
- 主要结局是72小时儿科序列器官衰竭评估 (pSOFA) 评分的变化.
主要成果:
- 静脉注射维生素C与安慰剂相比,并没有导致pSOFA得分的变化有显著差异.
- 在28天死亡率,冲击解消或其他次要结果方面没有显著差异.
- 诸如急性损伤等不良事件的发生率在维生素C和安慰剂组之间是相似的.
结论:
- 静脉注射维生素C并没有显著改善儿科败血症休克中器官功能障碍.
- 研究结果不支持常规使用维生素C作为儿童败血症休克的辅助治疗.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:28Pneumonia IV: Management
451
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
451